Journal
MEDCHEMCOMM
Volume 8, Issue 4, Pages 725-729Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c6md00539j
Keywords
-
Ask authors/readers for more resources
Recently, our research group reported the identification of prodrug amino-alcohol 2 as a potent and efficacious S1P(1) receptor modulator. This molecule is differentiated preclinically over the marketed drug fingolimod (Gilenya 1), whose active phosphate metabolite is an S1P(1) full agonist, in terms of pulmonary and cardiovascular safety. S1P(1) partial agonist 2, however, has a long half-life in rodents and was projected to have a long half-life in humans. The purpose of this communication is to disclose highly potent partial agonists of S1P(1) with shorter half-lives relative to the clinical compound 2. PK/PD relationships as well as their preclinical pulmonary and cardiovascular safety assessment are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available